12 recruiting, 6 not yet recruiting, 2 active not recruiting, 2 completed. 16 Phase 1, 12 Phase 2, 3 Phase 3.
Follow revumenib: new trials by email Literature Review of revumenib trials Research Report on revumenib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Menin-Inhibitor Targeted Maintenance in AML Revumenib, Placebo - Relapsed Adult AML, Stem Cell Transplant Complications | Phase 2 | Not yet recruiting | Center for International Blood and Marrow Transplant Research | 146 | 2026-12-01 | 2026-06-22 |
| Revumenib in Patients With Myelofibrosis Revumenib, Ruxolitinib, FEDRATINIB - Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 1 / Phase 2 | Not yet recruiting | John Mascarenhas | 32 | 2026-12-01 | 2026-07-29 |
| A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia Revumenib, Blinatumomab - Blinatumomab, Revumenib | Phase 1 | Not yet recruiting | M.D. Anderson Cancer Center | 20 | 2026-11-18 | 2026-08-12 |
| Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration - Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia | Phase 2 | Not yet recruiting | SWOG Cancer Research Network | 90 | 2026-10-14 | 2026-10-13 |
| Revumenib, Azacitidine, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AML Azacitidine, Venetoclax, Revumenib - Leukemia Acute Myeloid | Phase 2 | Not yet recruiting | UNC Lineberger Comprehensive Cancer Center | 88 | 2026-10-01 | 2026-09-10 |
| A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 1 | Withdrawn | Children's Oncology Group | 2026-09-10 | 2026-05-05 | |
| Trial of Revumenib Plus FLA Chemotherapy for Children With Relapsed or Refractory NUP98-rearranged AML." Revumenib, Fludarabine, Cytarabine (Ara-C) - Leukemia, Myeloid, Acute | Phase 2 | Not yet recruiting | Therapeutic Advances in Childhood Leukemia Consortium | 24 | 2026-08-31 | 2026-07-22 |
| A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and Relapsed /Refractory Pediatric Acute Leukemia Patients Revumenib, Cytrabine, Daunorubicin - Pediatric Acute Leukemia | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2026-05-21 | 2026-09-23 | |
| A Study of Revumenib and Mezigdomide in People With Leukemia Revumenib, Mezigdomide - Leukemia, Acute Leukemia | Phase 1 / Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 52 | 2026-01-16 | 2026-10-20 |
| Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation Revumenib, Placebo, Intensive Chemotherapy Regimen - Acute Myeloid Leukemias | Phase 3 | Recruiting | Syndax Pharmaceuticals | 468 | 2025-11-25 | 2026-10-21 |
| Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML Revumenib, Placebo - Acute Myeloid Leukemia, Adult | Phase 3 | Recruiting | Stichting Hemato-Oncologie voor Volwassenen Nederland | 448 | 2025-05-05 | 2026-09-02 |
| Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Leukemia, Acute Leukemia of Ambiguous Lineage | Phase 1 | Recruiting | City of Hope Medical Center | 27 | 2024-12-31 | 2026-10-19 |
| Revumenib in Combination With 7+3 + Midostaurin in AML Revumenib, Midostaurin, Cytarabine - Acute Myeloid Leukemia, AML, Adult | Phase 1 | Recruiting | Richard Stone, MD | 22 | 2024-12-06 | 2026-03-25 |
| A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib Venetoclax, Revumenib - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 8 | 2024-09-23 | 2026-09-18 |
| A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia, Acute Myeloid Leukemia With KMT2A Rearrangement | Phase 1 | Recruiting | National Cancer Institute (NCI) | 38 | 2024-06-20 | 2026-08-25 |
| A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes Revumenib - Leukemia, HOX Gene | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 40 | 2024-06-04 | 2026-09-11 |
| A Study of Revumenib in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias Revumenib, Chemotherapy Regimen, HiDAC - Acute Myeloid Leukemias | Phase 1 | Active not recruiting | Syndax Pharmaceuticals | 96 | 2024-05-21 | 2026-09-16 |
| Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia Revumenib, Venetoclax, Azacitidine - Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia | Phase 1 | Recruiting | St. Jude Children's Research Hospital | 24 | 2024-04-19 | 2026-10-22 |
| SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Gilteritinib - Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With KMT2A Rearrangement | Phase 1 | Recruiting | Uma Borate | 30 | 2024-02-20 | 2026-05-14 |
| A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia Biospecimen Collection, Bone Marrow Aspiration, Calaspargase Pegol - Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia | Phase 2 | Active not recruiting | Children's Oncology Group | 78 | 2024-01-08 | 2026-08-25 |
Showing 20 of 26. Sign in to see all of them.
Leukemia, Myeloid, Acute (16) · Leukemia, Biphenotypic, Acute (8) · Leukemia (7) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (7) · Burkitt Lymphoma (1) · Colorectal Neoplasms (1) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1) · Primary Myelofibrosis (1) · Recurrence (1)
Syndax Pharmaceuticals (7) · M.D. Anderson Cancer Center (4) · Children's Oncology Group (2) · Beat AML, LLC (1) · Center for International Blood and Marrow Transplant Research (1) · City of Hope Medical Center (1) · John Mascarenhas (1) · Memorial Sloan Kettering Cancer Center (1) · National Cancer Institute (NCI) (1) · Richard Stone, MD (1) · SWOG Cancer Research Network (1) · St. Jude Children's Research Hospital (1) · Stichting Hemato-Oncologie voor Volwassenen Nederland (1) · Therapeutic Advances in Childhood Leukemia Consortium (1) · UNC Lineberger Comprehensive Cancer Center (1)
United States (21) · Canada (5) · Australia (4) · Spain (4) · France (3) · Germany (3) · Italy (3) · Lithuania (3) · Netherlands (3) · United Kingdom (3) · Austria (2) · Belgium (2) · Israel (2) · Argentina (1) · Brazil (1)
Ghayas Issa, MD (2) · Nicole McNeer, MD, PhD (2) · Alice Mims, MD (1) · Alice S Mims (1) · Angela R Smith, M.D. (1) · Anthony M Hunter, MD (1) · Ben K Watkins (1) · Branko Cuglievan, MD (1) · Brian Ball, MD (1) · Elias J Jabbour, MD (1) · Gerwin Huls, MD (1) · Hiroto Inaba, MD, PhD (1) · Ibrahim Aldoss (1) · John Mascarenhas, MD (1) · Joshua Zeidner, MD (1)
PMID 33741715, PMID 34267079, PMID 36922593, PMID 39121437, PMID 40332046, PMID 40504618, PMID 40557912, PMID 41621809
2025 (1), P01CA108671 (1), P30CA033572 (1), U10CA180886 (1), U10CA180888 (1), UM1CA186712 (1), UM1CA228823 (1)